Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_assertion type Assertion NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_head.
- NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_assertion description "[We analyzed the PIK3CA and KRAS mutation status in a large group (n = 200) of chemorefractory metastatic colorectal cancers treated with cetuximab (Erbitux) in monotherapy or in combination with irinotecan, and correlated the mutation status with outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_provenance.
- NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_assertion evidence source_evidence_literature NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_provenance.
- NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_assertion SIO_000772 19366826 NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_provenance.
- NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_assertion wasDerivedFrom befree-2016 NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_provenance.
- NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_assertion wasGeneratedBy ECO_0000203 NP732381.RAfKOxbsgya8QGVaArPCDNiJsvQAx1QxiteftI0cidBKU130_provenance.